Innovative Diagnostic Peptide-Based Technologies for Cancer Diagnosis: Focus on EGFR-Targeting Peptides.
Quick Facts
What This Study Found
Peptides targeting EGFR enhance diagnostic sensitivity for various cancers.
Key Numbers
How They Did This
The study is a review summarizing various peptide-based diagnostic technologies and their applications.
Why This Research Matters
Improving cancer diagnosis can lead to earlier detection and better treatment outcomes. Targeting EGFR with peptides may provide a more effective approach than traditional methods.
What This Study Doesn't Tell Us
As a review, it does not present new experimental data but summarizes existing studies, which may vary in quality.
Trust & Context
- Original Title:
- Innovative Diagnostic Peptide-Based Technologies for Cancer Diagnosis: Focus on EGFR-Targeting Peptides.
- Published In:
- ChemMedChem, 18(3), e202200506 (2023)
- Authors:
- Ahmadi, Mohammad, Ahmadyousefi, Yaghoub, Salimi, Zahra, Mirzaei, Rasoul, Najafi, Rezvan, Amirheidari, Bagher, Rahbarizadeh, Fatemeh, Kheshti, Javad, Safari, Armin, Soleimani, Meysam
- Database ID:
- RPEP-06672
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06672APA
Ahmadi, Mohammad; Ahmadyousefi, Yaghoub; Salimi, Zahra; Mirzaei, Rasoul; Najafi, Rezvan; Amirheidari, Bagher; Rahbarizadeh, Fatemeh; Kheshti, Javad; Safari, Armin; Soleimani, Meysam. (2023). Innovative Diagnostic Peptide-Based Technologies for Cancer Diagnosis: Focus on EGFR-Targeting Peptides.. ChemMedChem, 18(3), e202200506. https://doi.org/10.1002/cmdc.202200506
MLA
Ahmadi, Mohammad, et al. "Innovative Diagnostic Peptide-Based Technologies for Cancer Diagnosis: Focus on EGFR-Targeting Peptides.." ChemMedChem, 2023. https://doi.org/10.1002/cmdc.202200506
RethinkPeptides
RethinkPeptides Research Database. "Innovative Diagnostic Peptide-Based Technologies for Cancer ..." RPEP-06672. Retrieved from https://rethinkpeptides.com/research/ahmadi-2023-innovative-diagnostic-peptidebased-technologies
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.